PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.
PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.07. On average, analysts expect PMV Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
PMV Pharmaceuticals Stock Performance
Shares of PMVP opened at $1.17 on Wednesday. The company has a 50-day simple moving average of $1.20 and a 200-day simple moving average of $1.27. PMV Pharmaceuticals has a 52 week low of $1.02 and a 52 week high of $1.88. The firm has a market capitalization of $62.40 million, a P/E ratio of -0.79 and a beta of 1.34.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on PMVP
Institutional Trading of PMV Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Shay Capital LLC bought a new position in PMV Pharmaceuticals during the second quarter worth about $26,000. Squarepoint Ops LLC boosted its holdings in PMV Pharmaceuticals by 101.8% during the fourth quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock valued at $33,000 after purchasing an additional 13,367 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in shares of PMV Pharmaceuticals by 349.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock valued at $34,000 after purchasing an additional 21,334 shares during the period. Algert Global LLC bought a new stake in shares of PMV Pharmaceuticals in the 3rd quarter valued at approximately $87,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of PMV Pharmaceuticals in the 3rd quarter valued at approximately $96,000. Institutional investors own 90.20% of the company’s stock.
About PMV Pharmaceuticals
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.
Read More
- Five stocks we like better than PMV Pharmaceuticals
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
